(Q33731748)

English

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Chun-Jun Li

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Xiao-Juan Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lian Bai

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Qian Yu

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Qiu-Mei Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pei Yu

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

De-Min Yu

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

31 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Diabetology and Metabolic Syndrome

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Standards of medical care in diabetes--2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Projected and observed diabetes epidemics in China and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Prevalence of diabetes among men and women in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Global and societal implications of the diabetes epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050987

21 June 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1758-5996-6-69

21 January 2018

Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24917890

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24917890

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24917890

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24917890

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1758-5996-6-69

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33731748&oldid=2195708006"